ESR1 and breast carcinoma: To determine if the differential expression of miRNAs seen in the cell line models is observed in additional models, we used patient-derived xenograft (PDX) breast cancer models (66), harboring either WT ER or naturally-occurring heterozygous Y537S or L536P ER mutations.